NCT00621296View on ClinicalTrials.gov

Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Hepatitis C
Interventions
DRUG

MP-424 (Telaprevir)

Three tablets of MP-424 250mg tablet at a time, every 8 hours, 24 weeks administration (dose in a day: 2250 mg)

Trial Locations (1)

Unknown

Toranomon Hospital, Kawasaki

Sponsors
All Listed Sponsors
collaborator

Vertex Pharmaceuticals Incorporated

INDUSTRY

lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY